
via NIH
Researchers at Yale have identified a possible treatment for Duchenne muscular dystrophy (DMD), a rare genetic disease for which there is currently no cure or treatment, by targeting an enzyme that had been considered “undruggable.” The finding appears in the Aug. 25 edition of Science Signaling.
DMD is the most common form of muscular dystrophy, a disease that leads to progressive weakness and eventual loss of the skeletal and heart muscles. It occurs in 16 of 100,000 male births in the U.S. People with the disease exhibit clumsiness and weakness in early childhood and typically need wheelchairs by the time they reach their teens. The average life expectancy is 26.
While earlier research had revealed the crucial role played by an enzyme called MKP5 in the development of DMD, making it a promising target for possible treatment, scientists for decades had been unable to disrupt this family of enzymes, known as protein tyrosine phosphatases, at the enzymes’ “active” site where chemical reactions occur.
In the new study, Anton Bennett, the Dorys McConnell Duberg Professor of Pharmacology and professor of comparative medicine, and his team screened over 162,000 compounds. They identified one molecular compound that blocked the enzyme’s activity by binding to a previously undiscovered allosteric site — a spot near the enzyme’s active site.
“There have been many attempts to design inhibitors for this family of enzymes, but those compounds have failed to produce the right properties,” Bennett said. “Until now, the family of enzymes has been considered ‘undruggable.’”
By targeting the allosteric site of MKP5 instead, he said, “We discovered an excellent starting point for drug development that circumvented the earlier problems.”
The researchers tested their compound in muscle cells and found that it successfully inhibited MKP5 activity, suggesting a promising new therapeutic strategy for treating DMD.
The research was supported by a National Institutes of Health grant through the National Institute of Arthritis and Musculoskeletal and Skin Diseases, as well as by the Blavatnik Fund for Innovation at Yale, which annually presents awards to support the most promising life science discoveries from Yale faculty.
Bennett said that the Blavatnik funding, which is administered by the Yale Office of Cooperative Research, was critical in moving the research forward. “It resulted in a license with a major pharmaceutical company,” he said, “and we hope they will rapidly move forward with the development of the new treatment.”
The finding has implications well beyond muscular dystrophy, he added. The researchers have demonstrated that the MKP5 enzyme is broadly implicated in fibrosis, or the buildup of scar tissue, a condition that contributes to nearly one-third of natural deaths worldwide.
“Fibrosis is involved in the end-stage death of many tissues, including liver, lung, and muscle,” Bennett said. “We believe this enzyme could be a target more broadly for fibrotic tissue disease.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Duchenne muscular dystrophy
- Rare Disease Day: How Bengaluru startup Hanugen Therapeutics is developing a cure for Duchenne Muscular Dystrophyon February 27, 2021 at 10:38 am
Bengaluru-based Hanugen Therapeutics is developing a solution for treating Duchenne Muscular Dystrophy, a fatal rare disease.
- FDA Approves Third Sarepta Treatment For DMDon February 26, 2021 at 10:07 pm
The U.S. Food and Drug Administration approved Sarepta Therapeutics’ Amondys 45 (casimersen) for patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation amenable to exon 45 ...
- FDA waves through a third Sarepta DMD drug, once again based on questionable biomarker dataon February 26, 2021 at 7:56 am
Sarepta Therapeutics has pushed its third Duchenne muscular dystrophy drug across the FDA finish line—again with questionable biomarker data. But this time, the approval didn't come with the usual ...
- FDA OKs Targeted Tx for Duchenne Muscular Dystrophy Mutationon February 26, 2021 at 2:29 am
The FDA approved injectable casimersen (Amondys 45) as a targeted treatment Duchenne muscular dystrophy (DMD) in patients with a confirmed DMD gene mutation amenable to exon 45 skipping. “Developing ...
- Why not? Sarepta’s third Duchenne MD drug sails to accelerated approvalon February 26, 2021 at 2:02 am
Sarepta may be running into some trouble with its next-gen gene therapy approach to Duchenne muscular dystrophy. But when it comes to antisense oligonucleotides, the well-trodden regulatory path is ...
Go deeper with Google Headlines on:
Duchenne muscular dystrophy
Go deeper with Bing News on:
MKP5
- A Role for MK2 in Enhancing Neutrophil-Derived ROS Production and Aggravating Liver Ischemia/Reperfusion Injuryon February 3, 2021 at 4:00 pm
Hepatic ischemia/reperfusion (I/R) is a pathophysiologic process that can be triggered by liver transplantation, elective liver surgery, toxic liver injury, and hepatic sinusoidal obstruction syndrome ...
- MAP2K6 mitogen-activated protein kinase kinase 6 [ (human)]on February 2, 2021 at 4:00 pm
This gene encodes a member of the dual specificity protein kinase family, which functions as a mitogen-activated protein (MAP) kinase kinase. MAP kinases, also known as extracellular signal-regulated ...
- DUSP10 dual specificity phosphatase 10 [ (human)]on February 2, 2021 at 4:00 pm
Dual specificity protein phosphatases inactivate their target kinases by dephosphorylating both the phosphoserine/threonine and phosphotyrosine residues. They negatively regulate members of the MAP ...
- mTORC2 modulates feedback regulation of p38 MAPK activity via DUSP10/MKP5 to confer differential responses to PP242 in glioblastomaon July 13, 2020 at 3:54 am
@article{BenavidesSerrato2014mTORC2MF, title={mTORC2 modulates feedback regulation of p38 MAPK activity via DUSP10/MKP5 to confer differential responses to PP242 in glioblastoma}, author={A. Benavides ...
- Mice lacking MKP-1 and MKP-5 Reveal Hierarchical Regulation of Regenerative Myogenesis.on March 14, 2020 at 1:05 pm
@article{Shi2015MiceLM, title={Mice lacking MKP-1 and MKP-5 Reveal Hierarchical Regulation of Regenerative Myogenesis.}, author={H. Shi and Florian Gatzke and Julia M Molle and H. B. Lee and E. Helm ...